liraltagene autoleucel

N/A

Report date: 2025/11/21 10:27:54

Base Information

Drug Nameliraltagene autoleucel

Drug Alias NameFollicle Stimulating Hormone Receptor-Mediated CAR-T technologyCER-T Approachlira-cel

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionAnti-Follicle-stimulating hormone receptor

TargetsFollicle-stimulating hormone receptor

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAnixa Biosciences Inc Certainty Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAnixa Biosciences Inc H Lee Moffitt Cancer Center & Research Institute

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A